eduKateSG · Why Science?
Make biology reproducible at scale—connecting proteins, cells, nucleic acids, bioreactors, purification and quality
A fact-checked guide to A*STAR BTI and the evidence chain behind modern biomanufacturing processes and therapeutic modalities.
A*STAR BTI says it has advanced bioprocessing technologies over a 35-year history and now emphasises quality processes for biomanufacturing across proteins, cells and nucleic acids.
Its official capability map lists modality development, bioprocess technologies development, formulation and deliveries for genes, and analytical science and technology as four principal divisions.
Did you know? The biological factory and the final product influence each other: cell state, media, mixing and harvest timing can change product quality before purification begins.
This guide is educational and provides no manufacturing, clinical or regulatory authorisation. Official sources were checked 11 November 2026.
Chapter index
Chapters 1–9: bioprocessing, biomanufacturing, proteins, antibodies, cells, cell therapy, nucleic acids, mRNA, production systems
Chapters 10–17: media, bioreactors, scale-up, downstream processing, formulation, analytical characterisation, process control, quality and evidence receipts
Bioproducts may be proteins, cells, nucleic acids or other biologically produced materials with defined functions. Biomanufacturing asks living cells and biochemical systems to make products consistently at useful scale. A*STAR BTI describes a current emphasis on proteins, cells and nucleic acids and a vision of quality processes for biomanufacturing. Chapter 1 follows one link from biological design through cultivation, recovery, formulation, analytics and process control, where product quality must be built rather than inspected in at the end.
Specify identity, use, quality attributes and reference state. A defensible process records the production cell or system, raw materials, media, equipment, operating ranges, in-process controls, yield, impurities, critical quality attributes and storage. Teams combine cell engineering, bioreactor science, purification, formulation, analytical characterisation and modelling. Scale-down studies and continued verification help connect laboratory mechanisms with a process that can be repeated across batches.
A product name cannot define all required quality. High titre, a promising cell therapy or an elegant mRNA formulation does not establish a safe medicine or approved manufacturing process. Biological systems change, contamination can spread, and small differences can affect identity, potency or stability. Clinical, GMP and regulatory requirements depend on the product and stage. Classroom work must remain theoretical, simulated or use safe public data rather than engineered cells or biologics.
Use “Define the bioproduct” as a paper design or digital process exercise. Write a product profile concept. Define the product, unit operation, measurable quality attribute, control range, sampling point and failure response. Create a mass balance or control chart with fictional values. Explain which evidence belongs to discovery, process development, manufacturing and release instead of collapsing every stage into one success claim.
Did you know? A bioreactor is not merely a bigger flask. Mixing, gas transfer, heat removal, shear, sensors and cell history change with scale, while a heterogeneous cell population can respond in unexpected ways. Chapter 1 shows why engineers use scale-down models, mechanistic understanding and data-driven monitoring before assuming that a recipe will transfer.
Capabilities include molecular biology, cell culture, biochemical engineering, chemistry, analytics, mass spectrometry, formulation, automation, statistics, AI and quality systems. Students can begin with growth curves, rates, stoichiometry, separation models and charts. Current degrees, training and regulated roles set requirements; a strong bioprocess portfolio records batches, controls, deviations and uncertainty instead of promising a therapy or job.
Protein modalities depend on sequence, folding, modifications, assembly and stability. Biomanufacturing asks living cells and biochemical systems to make products consistently at useful scale. A*STAR BTI describes a current emphasis on proteins, cells and nucleic acids and a vision of quality processes for biomanufacturing. Chapter 2 follows one link from biological design through cultivation, recovery, formulation, analytics and process control, where product quality must be built rather than inspected in at the end.
Connect molecular design with expression and analytics. A defensible process records the production cell or system, raw materials, media, equipment, operating ranges, in-process controls, yield, impurities, critical quality attributes and storage. Teams combine cell engineering, bioreactor science, purification, formulation, analytical characterisation and modelling. Scale-down studies and continued verification help connect laboratory mechanisms with a process that can be repeated across batches.
Correct sequence alone does not guarantee correct function. High titre, a promising cell therapy or an elegant mRNA formulation does not establish a safe medicine or approved manufacturing process. Biological systems change, contamination can spread, and small differences can affect identity, potency or stability. Clinical, GMP and regulatory requirements depend on the product and stage. Classroom work must remain theoretical, simulated or use safe public data rather than engineered cells or biologics.
Use “Engineer proteins” as a paper design or digital process exercise. Build a protein-quality map. Define the product, unit operation, measurable quality attribute, control range, sampling point and failure response. Create a mass balance or control chart with fictional values. Explain which evidence belongs to discovery, process development, manufacturing and release instead of collapsing every stage into one success claim.
Did you know? A bioreactor is not merely a bigger flask. Mixing, gas transfer, heat removal, shear, sensors and cell history change with scale, while a heterogeneous cell population can respond in unexpected ways. Chapter 2 shows why engineers use scale-down models, mechanistic understanding and data-driven monitoring before assuming that a recipe will transfer.
Capabilities include molecular biology, cell culture, biochemical engineering, chemistry, analytics, mass spectrometry, formulation, automation, statistics, AI and quality systems. Students can begin with growth curves, rates, stoichiometry, separation models and charts. Current degrees, training and regulated roles set requirements; a strong bioprocess portfolio records batches, controls, deviations and uncertainty instead of promising a therapy or job.
Antibodies and multispecific formats require controlled expression, assembly and characterisation. Biomanufacturing asks living cells and biochemical systems to make products consistently at useful scale. A*STAR BTI describes a current emphasis on proteins, cells and nucleic acids and a vision of quality processes for biomanufacturing. Chapter 3 follows one link from biological design through cultivation, recovery, formulation, analytics and process control, where product quality must be built rather than inspected in at the end.
Measure binding, structure, purity, potency and stability. A defensible process records the production cell or system, raw materials, media, equipment, operating ranges, in-process controls, yield, impurities, critical quality attributes and storage. Teams combine cell engineering, bioreactor science, purification, formulation, analytical characterisation and modelling. Scale-down studies and continued verification help connect laboratory mechanisms with a process that can be repeated across batches.
Strong binding in one assay cannot prove clinical benefit. High titre, a promising cell therapy or an elegant mRNA formulation does not establish a safe medicine or approved manufacturing process. Biological systems change, contamination can spread, and small differences can affect identity, potency or stability. Clinical, GMP and regulatory requirements depend on the product and stage. Classroom work must remain theoretical, simulated or use safe public data rather than engineered cells or biologics.
Use “Develop antibodies and complex biologics” as a paper design or digital process exercise. Create an antibody evidence card. Define the product, unit operation, measurable quality attribute, control range, sampling point and failure response. Create a mass balance or control chart with fictional values. Explain which evidence belongs to discovery, process development, manufacturing and release instead of collapsing every stage into one success claim.
Did you know? A bioreactor is not merely a bigger flask. Mixing, gas transfer, heat removal, shear, sensors and cell history change with scale, while a heterogeneous cell population can respond in unexpected ways. Chapter 3 shows why engineers use scale-down models, mechanistic understanding and data-driven monitoring before assuming that a recipe will transfer.
Capabilities include molecular biology, cell culture, biochemical engineering, chemistry, analytics, mass spectrometry, formulation, automation, statistics, AI and quality systems. Students can begin with growth curves, rates, stoichiometry, separation models and charts. Current degrees, training and regulated roles set requirements; a strong bioprocess portfolio records batches, controls, deviations and uncertainty instead of promising a therapy or job.
Cell products combine identity, state, viability, function and process history. Biomanufacturing asks living cells and biochemical systems to make products consistently at useful scale. A*STAR BTI describes a current emphasis on proteins, cells and nucleic acids and a vision of quality processes for biomanufacturing. Chapter 4 follows one link from biological design through cultivation, recovery, formulation, analytics and process control, where product quality must be built rather than inspected in at the end.
Track source, expansion, phenotype, potency and safety. A defensible process records the production cell or system, raw materials, media, equipment, operating ranges, in-process controls, yield, impurities, critical quality attributes and storage. Teams combine cell engineering, bioreactor science, purification, formulation, analytical characterisation and modelling. Scale-down studies and continued verification help connect laboratory mechanisms with a process that can be repeated across batches.
Viable cells are not automatically the intended therapeutic cells. High titre, a promising cell therapy or an elegant mRNA formulation does not establish a safe medicine or approved manufacturing process. Biological systems change, contamination can spread, and small differences can affect identity, potency or stability. Clinical, GMP and regulatory requirements depend on the product and stage. Classroom work must remain theoretical, simulated or use safe public data rather than engineered cells or biologics.
Use “Manufacture living cells” as a paper design or digital process exercise. Draft a cell-product receipt. Define the product, unit operation, measurable quality attribute, control range, sampling point and failure response. Create a mass balance or control chart with fictional values. Explain which evidence belongs to discovery, process development, manufacturing and release instead of collapsing every stage into one success claim.
Did you know? A bioreactor is not merely a bigger flask. Mixing, gas transfer, heat removal, shear, sensors and cell history change with scale, while a heterogeneous cell population can respond in unexpected ways. Chapter 4 shows why engineers use scale-down models, mechanistic understanding and data-driven monitoring before assuming that a recipe will transfer.
Capabilities include molecular biology, cell culture, biochemical engineering, chemistry, analytics, mass spectrometry, formulation, automation, statistics, AI and quality systems. Students can begin with growth curves, rates, stoichiometry, separation models and charts. Current degrees, training and regulated roles set requirements; a strong bioprocess portfolio records batches, controls, deviations and uncertainty instead of promising a therapy or job.
| Evidence move | What to record | What it cannot prove alone |
|---|---|---|
| Bioproduct question | Population or system, variable, unit, comparator and time window | A definition does not establish a result |
| Quality check | Calibration, controls, uncertainty and version | One successful run does not prove general reliability |
| Decision boundary | Owner, trigger, review and escalation | A model or measurement does not replace accountable judgement |
Nucleic-acid modalities require sequence identity, integrity, purity, delivery and expression evidence. Biomanufacturing asks living cells and biochemical systems to make products consistently at useful scale. A*STAR BTI describes a current emphasis on proteins, cells and nucleic acids and a vision of quality processes for biomanufacturing. Chapter 5 follows one link from biological design through cultivation, recovery, formulation, analytics and process control, where product quality must be built rather than inspected in at the end.
Measure template, synthesis, contaminants, structure and function. A defensible process records the production cell or system, raw materials, media, equipment, operating ranges, in-process controls, yield, impurities, critical quality attributes and storage. Teams combine cell engineering, bioreactor science, purification, formulation, analytical characterisation and modelling. Scale-down studies and continued verification help connect laboratory mechanisms with a process that can be repeated across batches.
A correct sequence does not guarantee delivery or useful expression. High titre, a promising cell therapy or an elegant mRNA formulation does not establish a safe medicine or approved manufacturing process. Biological systems change, contamination can spread, and small differences can affect identity, potency or stability. Clinical, GMP and regulatory requirements depend on the product and stage. Classroom work must remain theoretical, simulated or use safe public data rather than engineered cells or biologics.
Use “Process nucleic acids” as a paper design or digital process exercise. Build an RNA quality chain. Define the product, unit operation, measurable quality attribute, control range, sampling point and failure response. Create a mass balance or control chart with fictional values. Explain which evidence belongs to discovery, process development, manufacturing and release instead of collapsing every stage into one success claim.
Did you know? A bioreactor is not merely a bigger flask. Mixing, gas transfer, heat removal, shear, sensors and cell history change with scale, while a heterogeneous cell population can respond in unexpected ways. Chapter 5 shows why engineers use scale-down models, mechanistic understanding and data-driven monitoring before assuming that a recipe will transfer.
Capabilities include molecular biology, cell culture, biochemical engineering, chemistry, analytics, mass spectrometry, formulation, automation, statistics, AI and quality systems. Students can begin with growth curves, rates, stoichiometry, separation models and charts. Current degrees, training and regulated roles set requirements; a strong bioprocess portfolio records batches, controls, deviations and uncertainty instead of promising a therapy or job.
Production cells or organisms must make the intended product consistently under defined conditions. Biomanufacturing asks living cells and biochemical systems to make products consistently at useful scale. A*STAR BTI describes a current emphasis on proteins, cells and nucleic acids and a vision of quality processes for biomanufacturing. Chapter 6 follows one link from biological design through cultivation, recovery, formulation, analytics and process control, where product quality must be built rather than inspected in at the end.
Monitor genotype, phenotype, productivity and stability. A defensible process records the production cell or system, raw materials, media, equipment, operating ranges, in-process controls, yield, impurities, critical quality attributes and storage. Teams combine cell engineering, bioreactor science, purification, formulation, analytical characterisation and modelling. Scale-down studies and continued verification help connect laboratory mechanisms with a process that can be repeated across batches.
A high-producing clone may drift or fail at scale. High titre, a promising cell therapy or an elegant mRNA formulation does not establish a safe medicine or approved manufacturing process. Biological systems change, contamination can spread, and small differences can affect identity, potency or stability. Clinical, GMP and regulatory requirements depend on the product and stage. Classroom work must remain theoretical, simulated or use safe public data rather than engineered cells or biologics.
Use “Engineer production systems” as a paper design or digital process exercise. Create a production-system card. Define the product, unit operation, measurable quality attribute, control range, sampling point and failure response. Create a mass balance or control chart with fictional values. Explain which evidence belongs to discovery, process development, manufacturing and release instead of collapsing every stage into one success claim.
Did you know? A bioreactor is not merely a bigger flask. Mixing, gas transfer, heat removal, shear, sensors and cell history change with scale, while a heterogeneous cell population can respond in unexpected ways. Chapter 6 shows why engineers use scale-down models, mechanistic understanding and data-driven monitoring before assuming that a recipe will transfer.
Capabilities include molecular biology, cell culture, biochemical engineering, chemistry, analytics, mass spectrometry, formulation, automation, statistics, AI and quality systems. Students can begin with growth curves, rates, stoichiometry, separation models and charts. Current degrees, training and regulated roles set requirements; a strong bioprocess portfolio records batches, controls, deviations and uncertainty instead of promising a therapy or job.
Media supply nutrients and signals that shape growth, metabolism and product quality. Biomanufacturing asks living cells and biochemical systems to make products consistently at useful scale. A*STAR BTI describes a current emphasis on proteins, cells and nucleic acids and a vision of quality processes for biomanufacturing. Chapter 7 follows one link from biological design through cultivation, recovery, formulation, analytics and process control, where product quality must be built rather than inspected in at the end.
Use controlled formulation, analytics and mechanistic reasoning. A defensible process records the production cell or system, raw materials, media, equipment, operating ranges, in-process controls, yield, impurities, critical quality attributes and storage. Teams combine cell engineering, bioreactor science, purification, formulation, analytical characterisation and modelling. Scale-down studies and continued verification help connect laboratory mechanisms with a process that can be repeated across batches.
Faster growth does not necessarily improve product quality. High titre, a promising cell therapy or an elegant mRNA formulation does not establish a safe medicine or approved manufacturing process. Biological systems change, contamination can spread, and small differences can affect identity, potency or stability. Clinical, GMP and regulatory requirements depend on the product and stage. Classroom work must remain theoretical, simulated or use safe public data rather than engineered cells or biologics.
Use “Design media and feeds” as a paper design or digital process exercise. Map media inputs to outputs. Define the product, unit operation, measurable quality attribute, control range, sampling point and failure response. Create a mass balance or control chart with fictional values. Explain which evidence belongs to discovery, process development, manufacturing and release instead of collapsing every stage into one success claim.
Did you know? A bioreactor is not merely a bigger flask. Mixing, gas transfer, heat removal, shear, sensors and cell history change with scale, while a heterogeneous cell population can respond in unexpected ways. Chapter 7 shows why engineers use scale-down models, mechanistic understanding and data-driven monitoring before assuming that a recipe will transfer.
Capabilities include molecular biology, cell culture, biochemical engineering, chemistry, analytics, mass spectrometry, formulation, automation, statistics, AI and quality systems. Students can begin with growth curves, rates, stoichiometry, separation models and charts. Current degrees, training and regulated roles set requirements; a strong bioprocess portfolio records batches, controls, deviations and uncertainty instead of promising a therapy or job.
Bioreactors control a living culture through mixing, gases, temperature, pH and feeding. Biomanufacturing asks living cells and biochemical systems to make products consistently at useful scale. A*STAR BTI describes a current emphasis on proteins, cells and nucleic acids and a vision of quality processes for biomanufacturing. Chapter 8 follows one link from biological design through cultivation, recovery, formulation, analytics and process control, where product quality must be built rather than inspected in at the end.
Track gradients, sensors, rates and deviations. A defensible process records the production cell or system, raw materials, media, equipment, operating ranges, in-process controls, yield, impurities, critical quality attributes and storage. Teams combine cell engineering, bioreactor science, purification, formulation, analytical characterisation and modelling. Scale-down studies and continued verification help connect laboratory mechanisms with a process that can be repeated across batches.
Setpoints cannot guarantee uniform conditions everywhere. High titre, a promising cell therapy or an elegant mRNA formulation does not establish a safe medicine or approved manufacturing process. Biological systems change, contamination can spread, and small differences can affect identity, potency or stability. Clinical, GMP and regulatory requirements depend on the product and stage. Classroom work must remain theoretical, simulated or use safe public data rather than engineered cells or biologics.
Use “Run bioreactors” as a paper design or digital process exercise. Draw a reactor control loop. Define the product, unit operation, measurable quality attribute, control range, sampling point and failure response. Create a mass balance or control chart with fictional values. Explain which evidence belongs to discovery, process development, manufacturing and release instead of collapsing every stage into one success claim.
Did you know? A bioreactor is not merely a bigger flask. Mixing, gas transfer, heat removal, shear, sensors and cell history change with scale, while a heterogeneous cell population can respond in unexpected ways. Chapter 8 shows why engineers use scale-down models, mechanistic understanding and data-driven monitoring before assuming that a recipe will transfer.
Capabilities include molecular biology, cell culture, biochemical engineering, chemistry, analytics, mass spectrometry, formulation, automation, statistics, AI and quality systems. Students can begin with growth curves, rates, stoichiometry, separation models and charts. Current degrees, training and regulated roles set requirements; a strong bioprocess portfolio records batches, controls, deviations and uncertainty instead of promising a therapy or job.
| Evidence move | What to record | What it cannot prove alone |
|---|---|---|
| Bioreactor process question | Population or system, variable, unit, comparator and time window | A definition does not establish a result |
| Quality check | Calibration, controls, uncertainty and version | One successful run does not prove general reliability |
| Decision boundary | Owner, trigger, review and escalation | A model or measurement does not replace accountable judgement |
Scale-up builds production capacity while scale-down models reproduce selected large-scale stresses. Biomanufacturing asks living cells and biochemical systems to make products consistently at useful scale. A*STAR BTI describes a current emphasis on proteins, cells and nucleic acids and a vision of quality processes for biomanufacturing. Chapter 9 follows one link from biological design through cultivation, recovery, formulation, analytics and process control, where product quality must be built rather than inspected in at the end.
Use transport criteria, representative ranges and comparability. A defensible process records the production cell or system, raw materials, media, equipment, operating ranges, in-process controls, yield, impurities, critical quality attributes and storage. Teams combine cell engineering, bioreactor science, purification, formulation, analytical characterisation and modelling. Scale-down studies and continued verification help connect laboratory mechanisms with a process that can be repeated across batches.
Geometric similarity alone cannot preserve biological behaviour. High titre, a promising cell therapy or an elegant mRNA formulation does not establish a safe medicine or approved manufacturing process. Biological systems change, contamination can spread, and small differences can affect identity, potency or stability. Clinical, GMP and regulatory requirements depend on the product and stage. Classroom work must remain theoretical, simulated or use safe public data rather than engineered cells or biologics.
Use “Scale up and scale down” as a paper design or digital process exercise. Build a scale bridge. Define the product, unit operation, measurable quality attribute, control range, sampling point and failure response. Create a mass balance or control chart with fictional values. Explain which evidence belongs to discovery, process development, manufacturing and release instead of collapsing every stage into one success claim.
Did you know? A bioreactor is not merely a bigger flask. Mixing, gas transfer, heat removal, shear, sensors and cell history change with scale, while a heterogeneous cell population can respond in unexpected ways. Chapter 9 shows why engineers use scale-down models, mechanistic understanding and data-driven monitoring before assuming that a recipe will transfer.
Capabilities include molecular biology, cell culture, biochemical engineering, chemistry, analytics, mass spectrometry, formulation, automation, statistics, AI and quality systems. Students can begin with growth curves, rates, stoichiometry, separation models and charts. Current degrees, training and regulated roles set requirements; a strong bioprocess portfolio records batches, controls, deviations and uncertainty instead of promising a therapy or job.
Harvest separates product-containing material from cells, debris or other process components. Biomanufacturing asks living cells and biochemical systems to make products consistently at useful scale. A*STAR BTI describes a current emphasis on proteins, cells and nucleic acids and a vision of quality processes for biomanufacturing. Chapter 10 follows one link from biological design through cultivation, recovery, formulation, analytics and process control, where product quality must be built rather than inspected in at the end.
Measure recovery, damage, impurities and hold time. A defensible process records the production cell or system, raw materials, media, equipment, operating ranges, in-process controls, yield, impurities, critical quality attributes and storage. Teams combine cell engineering, bioreactor science, purification, formulation, analytical characterisation and modelling. Scale-down studies and continued verification help connect laboratory mechanisms with a process that can be repeated across batches.
A clear liquid is not necessarily a pure product. High titre, a promising cell therapy or an elegant mRNA formulation does not establish a safe medicine or approved manufacturing process. Biological systems change, contamination can spread, and small differences can affect identity, potency or stability. Clinical, GMP and regulatory requirements depend on the product and stage. Classroom work must remain theoretical, simulated or use safe public data rather than engineered cells or biologics.
Use “Harvest and clarify” as a paper design or digital process exercise. Create a harvest balance. Define the product, unit operation, measurable quality attribute, control range, sampling point and failure response. Create a mass balance or control chart with fictional values. Explain which evidence belongs to discovery, process development, manufacturing and release instead of collapsing every stage into one success claim.
Did you know? A bioreactor is not merely a bigger flask. Mixing, gas transfer, heat removal, shear, sensors and cell history change with scale, while a heterogeneous cell population can respond in unexpected ways. Chapter 10 shows why engineers use scale-down models, mechanistic understanding and data-driven monitoring before assuming that a recipe will transfer.
Capabilities include molecular biology, cell culture, biochemical engineering, chemistry, analytics, mass spectrometry, formulation, automation, statistics, AI and quality systems. Students can begin with growth curves, rates, stoichiometry, separation models and charts. Current degrees, training and regulated roles set requirements; a strong bioprocess portfolio records batches, controls, deviations and uncertainty instead of promising a therapy or job.
Downstream processing separates product from impurities through staged operations. Biomanufacturing asks living cells and biochemical systems to make products consistently at useful scale. A*STAR BTI describes a current emphasis on proteins, cells and nucleic acids and a vision of quality processes for biomanufacturing. Chapter 11 follows one link from biological design through cultivation, recovery, formulation, analytics and process control, where product quality must be built rather than inspected in at the end.
Track yield, selectivity, capacity, clearance and consistency. A defensible process records the production cell or system, raw materials, media, equipment, operating ranges, in-process controls, yield, impurities, critical quality attributes and storage. Teams combine cell engineering, bioreactor science, purification, formulation, analytical characterisation and modelling. Scale-down studies and continued verification help connect laboratory mechanisms with a process that can be repeated across batches.
High final purity can hide low recovery or altered function. High titre, a promising cell therapy or an elegant mRNA formulation does not establish a safe medicine or approved manufacturing process. Biological systems change, contamination can spread, and small differences can affect identity, potency or stability. Clinical, GMP and regulatory requirements depend on the product and stage. Classroom work must remain theoretical, simulated or use safe public data rather than engineered cells or biologics.
Use “Purify bioproducts” as a paper design or digital process exercise. Build a purification train. Define the product, unit operation, measurable quality attribute, control range, sampling point and failure response. Create a mass balance or control chart with fictional values. Explain which evidence belongs to discovery, process development, manufacturing and release instead of collapsing every stage into one success claim.
Did you know? A bioreactor is not merely a bigger flask. Mixing, gas transfer, heat removal, shear, sensors and cell history change with scale, while a heterogeneous cell population can respond in unexpected ways. Chapter 11 shows why engineers use scale-down models, mechanistic understanding and data-driven monitoring before assuming that a recipe will transfer.
Capabilities include molecular biology, cell culture, biochemical engineering, chemistry, analytics, mass spectrometry, formulation, automation, statistics, AI and quality systems. Students can begin with growth curves, rates, stoichiometry, separation models and charts. Current degrees, training and regulated roles set requirements; a strong bioprocess portfolio records batches, controls, deviations and uncertainty instead of promising a therapy or job.
Formulation protects a modality through storage, handling and delivery to its intended site. Biomanufacturing asks living cells and biochemical systems to make products consistently at useful scale. A*STAR BTI describes a current emphasis on proteins, cells and nucleic acids and a vision of quality processes for biomanufacturing. Chapter 12 follows one link from biological design through cultivation, recovery, formulation, analytics and process control, where product quality must be built rather than inspected in at the end.
Test compatibility, stability, particles, potency and container interactions. A defensible process records the production cell or system, raw materials, media, equipment, operating ranges, in-process controls, yield, impurities, critical quality attributes and storage. Teams combine cell engineering, bioreactor science, purification, formulation, analytical characterisation and modelling. Scale-down studies and continued verification help connect laboratory mechanisms with a process that can be repeated across batches.
A stable vial does not prove effective delivery in people. High titre, a promising cell therapy or an elegant mRNA formulation does not establish a safe medicine or approved manufacturing process. Biological systems change, contamination can spread, and small differences can affect identity, potency or stability. Clinical, GMP and regulatory requirements depend on the product and stage. Classroom work must remain theoretical, simulated or use safe public data rather than engineered cells or biologics.
Use “Formulate and deliver” as a paper design or digital process exercise. Create a formulation matrix. Define the product, unit operation, measurable quality attribute, control range, sampling point and failure response. Create a mass balance or control chart with fictional values. Explain which evidence belongs to discovery, process development, manufacturing and release instead of collapsing every stage into one success claim.
Did you know? A bioreactor is not merely a bigger flask. Mixing, gas transfer, heat removal, shear, sensors and cell history change with scale, while a heterogeneous cell population can respond in unexpected ways. Chapter 12 shows why engineers use scale-down models, mechanistic understanding and data-driven monitoring before assuming that a recipe will transfer.
Capabilities include molecular biology, cell culture, biochemical engineering, chemistry, analytics, mass spectrometry, formulation, automation, statistics, AI and quality systems. Students can begin with growth curves, rates, stoichiometry, separation models and charts. Current degrees, training and regulated roles set requirements; a strong bioprocess portfolio records batches, controls, deviations and uncertainty instead of promising a therapy or job.
| Evidence move | What to record | What it cannot prove alone |
|---|---|---|
| Quality system question | Population or system, variable, unit, comparator and time window | A definition does not establish a result |
| Quality check | Calibration, controls, uncertainty and version | One successful run does not prove general reliability |
| Decision boundary | Owner, trigger, review and escalation | A model or measurement does not replace accountable judgement |
Analytical science measures identity, structure, purity, potency and process understanding. Biomanufacturing asks living cells and biochemical systems to make products consistently at useful scale. A*STAR BTI describes a current emphasis on proteins, cells and nucleic acids and a vision of quality processes for biomanufacturing. Chapter 13 follows one link from biological design through cultivation, recovery, formulation, analytics and process control, where product quality must be built rather than inspected in at the end.
Use orthogonal, calibrated and fit-for-purpose methods. A defensible process records the production cell or system, raw materials, media, equipment, operating ranges, in-process controls, yield, impurities, critical quality attributes and storage. Teams combine cell engineering, bioreactor science, purification, formulation, analytical characterisation and modelling. Scale-down studies and continued verification help connect laboratory mechanisms with a process that can be repeated across batches.
One assay cannot characterise a complex biologic completely. High titre, a promising cell therapy or an elegant mRNA formulation does not establish a safe medicine or approved manufacturing process. Biological systems change, contamination can spread, and small differences can affect identity, potency or stability. Clinical, GMP and regulatory requirements depend on the product and stage. Classroom work must remain theoretical, simulated or use safe public data rather than engineered cells or biologics.
Use “Characterise analytically” as a paper design or digital process exercise. Draft an analytical panel. Define the product, unit operation, measurable quality attribute, control range, sampling point and failure response. Create a mass balance or control chart with fictional values. Explain which evidence belongs to discovery, process development, manufacturing and release instead of collapsing every stage into one success claim.
Did you know? A bioreactor is not merely a bigger flask. Mixing, gas transfer, heat removal, shear, sensors and cell history change with scale, while a heterogeneous cell population can respond in unexpected ways. Chapter 13 shows why engineers use scale-down models, mechanistic understanding and data-driven monitoring before assuming that a recipe will transfer.
Capabilities include molecular biology, cell culture, biochemical engineering, chemistry, analytics, mass spectrometry, formulation, automation, statistics, AI and quality systems. Students can begin with growth curves, rates, stoichiometry, separation models and charts. Current degrees, training and regulated roles set requirements; a strong bioprocess portfolio records batches, controls, deviations and uncertainty instead of promising a therapy or job.
Mechanistic models, statistics and AI can support media design, control and fault detection. Biomanufacturing asks living cells and biochemical systems to make products consistently at useful scale. A*STAR BTI describes a current emphasis on proteins, cells and nucleic acids and a vision of quality processes for biomanufacturing. Chapter 14 follows one link from biological design through cultivation, recovery, formulation, analytics and process control, where product quality must be built rather than inspected in at the end.
Validate inputs, assumptions, uncertainty and update rules. A defensible process records the production cell or system, raw materials, media, equipment, operating ranges, in-process controls, yield, impurities, critical quality attributes and storage. Teams combine cell engineering, bioreactor science, purification, formulation, analytical characterisation and modelling. Scale-down studies and continued verification help connect laboratory mechanisms with a process that can be repeated across batches.
A model cannot repair poor sensors or missing biology. High titre, a promising cell therapy or an elegant mRNA formulation does not establish a safe medicine or approved manufacturing process. Biological systems change, contamination can spread, and small differences can affect identity, potency or stability. Clinical, GMP and regulatory requirements depend on the product and stage. Classroom work must remain theoretical, simulated or use safe public data rather than engineered cells or biologics.
Use “Model and monitor processes” as a paper design or digital process exercise. Build a monitoring plan. Define the product, unit operation, measurable quality attribute, control range, sampling point and failure response. Create a mass balance or control chart with fictional values. Explain which evidence belongs to discovery, process development, manufacturing and release instead of collapsing every stage into one success claim.
Did you know? A bioreactor is not merely a bigger flask. Mixing, gas transfer, heat removal, shear, sensors and cell history change with scale, while a heterogeneous cell population can respond in unexpected ways. Chapter 14 shows why engineers use scale-down models, mechanistic understanding and data-driven monitoring before assuming that a recipe will transfer.
Capabilities include molecular biology, cell culture, biochemical engineering, chemistry, analytics, mass spectrometry, formulation, automation, statistics, AI and quality systems. Students can begin with growth curves, rates, stoichiometry, separation models and charts. Current degrees, training and regulated roles set requirements; a strong bioprocess portfolio records batches, controls, deviations and uncertainty instead of promising a therapy or job.
Contamination control spans materials, people, equipment, facilities, methods and detection. Biomanufacturing asks living cells and biochemical systems to make products consistently at useful scale. A*STAR BTI describes a current emphasis on proteins, cells and nucleic acids and a vision of quality processes for biomanufacturing. Chapter 15 follows one link from biological design through cultivation, recovery, formulation, analytics and process control, where product quality must be built rather than inspected in at the end.
Use layered prevention, monitoring and response. A defensible process records the production cell or system, raw materials, media, equipment, operating ranges, in-process controls, yield, impurities, critical quality attributes and storage. Teams combine cell engineering, bioreactor science, purification, formulation, analytical characterisation and modelling. Scale-down studies and continued verification help connect laboratory mechanisms with a process that can be repeated across batches.
One negative test does not guarantee an entire process is contamination-free. High titre, a promising cell therapy or an elegant mRNA formulation does not establish a safe medicine or approved manufacturing process. Biological systems change, contamination can spread, and small differences can affect identity, potency or stability. Clinical, GMP and regulatory requirements depend on the product and stage. Classroom work must remain theoretical, simulated or use safe public data rather than engineered cells or biologics.
Use “Control contamination” as a paper design or digital process exercise. Map a contamination barrier. Define the product, unit operation, measurable quality attribute, control range, sampling point and failure response. Create a mass balance or control chart with fictional values. Explain which evidence belongs to discovery, process development, manufacturing and release instead of collapsing every stage into one success claim.
Did you know? A bioreactor is not merely a bigger flask. Mixing, gas transfer, heat removal, shear, sensors and cell history change with scale, while a heterogeneous cell population can respond in unexpected ways. Chapter 15 shows why engineers use scale-down models, mechanistic understanding and data-driven monitoring before assuming that a recipe will transfer.
Capabilities include molecular biology, cell culture, biochemical engineering, chemistry, analytics, mass spectrometry, formulation, automation, statistics, AI and quality systems. Students can begin with growth curves, rates, stoichiometry, separation models and charts. Current degrees, training and regulated roles set requirements; a strong bioprocess portfolio records batches, controls, deviations and uncertainty instead of promising a therapy or job.
Quality processes connect design knowledge, controls, data integrity, deviations and continual learning. Biomanufacturing asks living cells and biochemical systems to make products consistently at useful scale. A*STAR BTI describes a current emphasis on proteins, cells and nucleic acids and a vision of quality processes for biomanufacturing. Chapter 16 follows one link from biological design through cultivation, recovery, formulation, analytics and process control, where product quality must be built rather than inspected in at the end.
Define critical attributes, parameters and change governance. A defensible process records the production cell or system, raw materials, media, equipment, operating ranges, in-process controls, yield, impurities, critical quality attributes and storage. Teams combine cell engineering, bioreactor science, purification, formulation, analytical characterisation and modelling. Scale-down studies and continued verification help connect laboratory mechanisms with a process that can be repeated across batches.
Documentation alone cannot create product quality. High titre, a promising cell therapy or an elegant mRNA formulation does not establish a safe medicine or approved manufacturing process. Biological systems change, contamination can spread, and small differences can affect identity, potency or stability. Clinical, GMP and regulatory requirements depend on the product and stage. Classroom work must remain theoretical, simulated or use safe public data rather than engineered cells or biologics.
Use “Build quality processes” as a paper design or digital process exercise. Create a process-control strategy. Define the product, unit operation, measurable quality attribute, control range, sampling point and failure response. Create a mass balance or control chart with fictional values. Explain which evidence belongs to discovery, process development, manufacturing and release instead of collapsing every stage into one success claim.
Did you know? A bioreactor is not merely a bigger flask. Mixing, gas transfer, heat removal, shear, sensors and cell history change with scale, while a heterogeneous cell population can respond in unexpected ways. Chapter 16 shows why engineers use scale-down models, mechanistic understanding and data-driven monitoring before assuming that a recipe will transfer.
Capabilities include molecular biology, cell culture, biochemical engineering, chemistry, analytics, mass spectrometry, formulation, automation, statistics, AI and quality systems. Students can begin with growth curves, rates, stoichiometry, separation models and charts. Current degrees, training and regulated roles set requirements; a strong bioprocess portfolio records batches, controls, deviations and uncertainty instead of promising a therapy or job.
The receipt links product, cells, materials, equipment, process, analytics and accountable release decisions. Biomanufacturing asks living cells and biochemical systems to make products consistently at useful scale. A*STAR BTI describes a current emphasis on proteins, cells and nucleic acids and a vision of quality processes for biomanufacturing. Chapter 17 follows one link from biological design through cultivation, recovery, formulation, analytics and process control, where product quality must be built rather than inspected in at the end.
Archive batches, methods, deviations, models, changes and uncertainty. A defensible process records the production cell or system, raw materials, media, equipment, operating ranges, in-process controls, yield, impurities, critical quality attributes and storage. Teams combine cell engineering, bioreactor science, purification, formulation, analytical characterisation and modelling. Scale-down studies and continued verification help connect laboratory mechanisms with a process that can be repeated across batches.
A research receipt cannot replace GMP or regulatory approval. High titre, a promising cell therapy or an elegant mRNA formulation does not establish a safe medicine or approved manufacturing process. Biological systems change, contamination can spread, and small differences can affect identity, potency or stability. Clinical, GMP and regulatory requirements depend on the product and stage. Classroom work must remain theoretical, simulated or use safe public data rather than engineered cells or biologics.
Use “Keep a biomanufacturing receipt” as a paper design or digital process exercise. Assemble a one-page receipt. Define the product, unit operation, measurable quality attribute, control range, sampling point and failure response. Create a mass balance or control chart with fictional values. Explain which evidence belongs to discovery, process development, manufacturing and release instead of collapsing every stage into one success claim.
Did you know? A bioreactor is not merely a bigger flask. Mixing, gas transfer, heat removal, shear, sensors and cell history change with scale, while a heterogeneous cell population can respond in unexpected ways. Chapter 17 shows why engineers use scale-down models, mechanistic understanding and data-driven monitoring before assuming that a recipe will transfer.
Capabilities include molecular biology, cell culture, biochemical engineering, chemistry, analytics, mass spectrometry, formulation, automation, statistics, AI and quality systems. Students can begin with growth curves, rates, stoichiometry, separation models and charts. Current degrees, training and regulated roles set requirements; a strong bioprocess portfolio records batches, controls, deviations and uncertainty instead of promising a therapy or job.
| Evidence move | What to record | What it cannot prove alone |
|---|---|---|
| Biomanufacturing evidence question | Population or system, variable, unit, comparator and time window | A definition does not establish a result |
| Quality check | Calibration, controls, uncertainty and version | One successful run does not prove general reliability |
| Decision boundary | Owner, trigger, review and escalation | A model or measurement does not replace accountable judgement |
Contents · Previous chapter · Continue in the Science Learning Hub
Frequently asked questions
What does A*STAR BTI research?
BTI develops bioprocessing and biomanufacturing technologies with official focus areas in proteins, cells and nucleic acids and capabilities across modality, process, formulation, delivery and analytics.
What is a critical quality attribute?
It is a measurable physical, chemical, biological or microbiological property that should remain within an appropriate limit or range to assure desired product quality.
Why does scale-up change a bioprocess?
Larger vessels alter mixing, gas transfer, heat, shear, gradients, sensors and residence times, which can change cells and products.
Does high yield mean a process is ready?
No. Identity, purity, potency, safety, consistency, stability, manufacturability and regulatory evidence also matter.
Which school subjects support bioprocessing?
Biology and chemistry are central, with mathematics, physics, computing and engineering supporting kinetics, transport, analytics and process control.
Primary sources and verification date
Source status for Why Science? | Bioprocessing Technology Institute was checked 11 November 2026. Research priorities, programmes, facilities and participation routes can change; use the linked official owner for the current edition.
- A*STAR Bioprocessing Technology Institute — Official institute vision, focus areas and research highlights.
- BTI Key Focus Areas — Official proteins, cells and nucleic-acids strategy.
- BTI Core Capabilities — Official four-division capability structure.
- BTI Scientific Equipment and Services Profile — Official integrated bioprocess science and engineering capability context.
- Continuous Biomanufacturing Downstream Processing — Official research-highlight context for continuous downstream processing.
Continue the evidence journey
Biomanufacturing earns trust when biological design, process engineering, analytics, quality and scale remain one reviewable chain. Families considering science tuition or a science tutor can use the same evidence questions: what will the learner practise, what feedback will they receive, and how will progress be shown?